Elsevier

Metabolism

Volume 135, October 2022, 155270
Metabolism

Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases

https://doi.org/10.1016/j.metabol.2022.155270Get rights and content

Highlights

  • We performed Mendelian randomization analysis to dissect the association of NAFLD with 34 extrahepatic diseases.

  • MR estimates suggested that NAFLD was causally associated with a set of extrahepatic diseases.

  • NAFLD deserves a high priority in clinical practice.

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is prevalent worldwide and is associated with the risk of many extrahepatic diseases. However, whether NAFLD is a risk marker or a common cause of extrahepatic diseases is unclear.

Methods

We searched PubMed to identify NAFLD-related extrahepatic diseases. Genetic instrumental variables (IVs) for NAFLD surrogated by chronically elevated alanine transaminase levels and eligible extrahepatic diseases were retrieved from the corresponding genome-wide association analysis. We proposed a procedure for Mendelian randomization (MR) analysis and performed validation analyses to dissect the association between NAFLD and extrahepatic diseases. The Bonferroni method was used to correct the bias of multiple testing.

Results

In total, 34 extrahepatic diseases were included and 54 SNPs were used as IVs for NAFLD. The MR analysis gave a robust and significant (or suggestive) estimate for the association between NAFLD and 9 extrahepatic diseases: type 2 diabetes (odds ratio [OR] = 1.182, 95 % confidence interval [CI] 1.125–1.243, P = 5.40 × 10−11), cholelithiasis (OR = 1.171, 95%CI 1.083–1.266, P = 7.47 × 10−5), diabetic hypoglycemia (OR = 1.170, 95%CI 1.071–1.279, P = 5.14 × 10−4), myocardial infarction (OR = 1.122, 95%CI 1.057–1.190, P = 1.46 × 10−4), hypertension (OR = 1.060, 95%CI 1.029–1.093, P = 1.18 × 10−4), coronary artery disease (OR = 1.052, 95%CI 1.010–1.097, P = 1.58 × 10−2), heart failure (OR = 1.047, 95%CI 1.006–1.090, P = 2.44 × 10−2), dementia (OR = 0.881, 95%CI 0.806–0.962, P = 5.01 × 10−3), and pancreatic cancer (OR = 0.802, 95%CI 0.654–0.983, P = 3.32 × 10−2). Validation analyses using IVs from biopsy-confirmed and imaging-determined NAFLD reported similar results to the main analysis. For the remaining 25 outcomes, no significant or definitive association was yielded in MR analysis.

Conclusions

Genetic evidence suggests putative causal relationships between NAFLD and a set of extrahepatic diseases, indicating that NAFLD deserves high priority in clinical practice.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is a burgeoning public health concern worldwide and has reached the pandemic level with a recent prevalence estimate of 29.8 % [1], [2]. NAFLD was deemed a multisystem disease that increases the risks of intrahepatic diseases, and also affects the risks of extrahepatic diseases including cardiovascular diseases, type 2 diabetes (T2D), chronic kidney disease, and extrahepatic malignancies [3], [4]. A large body of observational studies have assessed the correlations between NAFLD and extrahepatic diseases, but conflicting results remain. For instance, prior studies reported that NAFLD was associated with an increased risk of stroke and cardiovascular events [5], [6], [7], [8]. The association was maintained after adjustment for metabolic components. However, a matched cohort study of 18 million European adults reported null associations between NAFLD and acute myocardial infarction and stroke [9].

The inconsistency between observational studies might be ascribed to potential limitations including different measurements for NAFLD (e.g., ultrasound vs. biomarkers), insufficient adjustment for confounders (e.g., metabolic traits), population heterogeneity, and short follow-up times. Moreover, estimates from observational studies are vulnerable to reverse causality. Mendelian randomization (MR) analysis using genetic information is less susceptible to unmeasured confounders and reverse causality because alleles are randomly assigned during meiosis and are independent of environmental exposures [10]. More importantly, MR analysis interprets association as evidence that the exposure has a causal effect on the outcome [11].

Several MR studies have been conducted to examine the association between NAFLD and extrahepatic diseases. For example, Liu et al. reported that genetically determined NAFLD causally promotes T2D [12]. Wu et al. found that NAFLD confers a causal effect on two subtypes of stroke [13]. However, the prior MR analyses mostly used a small number of genetic instrumental variables (IVs) for NAFLD and gave inconsistent findings. For instance, Lauridsen et al. used PNPLA3 rs738409 as an IV and found that genetic NAFLD was not causally associated with risk of ischemic heart disease [14]. Another MR study using eight IVs reported a significantly positive association between NAFLD and coronary artery disease (CAD) [15]. Given the inconsistency between MR studies, an orchestrated MR analysis procedure and more valid IVs are needed to yield robust conclusions. Additionally, the associations between NAFLD and most extrahepatic diseases have not yet been assessed using MR methods. Whether NAFLD is an active contributor or just an innocent bystander for the disease of interest is still unclear and warrants further investigation.

Section snippets

Literature search

We conducted a literature search in PubMed to identify NAFLD-related extrahepatic diseases on March 1, 2022. The search strategy is shown in Supplementary Table S1 and yielded a total of 1176 publications for screening. The inclusion criteria were as follows: (1) cohort, prospective, or longitudinal study design, or meta-analysis on these types of studies; (2) reporting a statistically significant risk ratio or hazard ratio; (3) the exposure was NAFLD; and (4) the primary outcome was

Statistics for instrumental variables

For MR analysis of the association between NAFLD and 34 extrahepatic diseases, the number of included SNPs ranged from 30 to 54, explaining 9.2 % to 15.7 % of the total variance in NAFLD (Supplementary Tables S2–3). All of the mean-F statistics were >400, and the values of IGX2 were >95%, suggesting low probabilities for weak IV and measurement error biases. In the current scenario, the MR analysis has sufficient statistical power (>80 %) to detect a minor association (OR in 0.95–1.05) between

Discussion

In the present study, we assessed the causal relationships between NAFLD and 34 extrahepatic diseases that showed a significantly positive association with NAFLD in observational studies. The MR analyses suggested that NAFLD was causally correlated with an increased risk of two endocrine diseases (i.e., T2D and DH), four circulatory diseases (i.e., CAD, MI, HF, and hypertension), and a digestive disease (i.e., cholelithiasis). In contrast, NAFLD was causally associated with a decreased risk of

Financial support statement

National Postdoctoral Program for Innovative Talents (grant number: BX2021077); China Postdoctoral Science Foundation (grant number: 2021M700841); National Natural Science Foundation of China (grant numbers: 820736378, 82122060); the National Key Research and Development Program of China (grant numbers: 2019YFC1315804, 2019FY101103).

Data availability statement

The sources of GWAS summary data used in the present study are shown in Table 1.

CRediT authorship contribution statement

ZL conceived the study design. ZL and HF performed the statistical analysis. ZL and CS wrote the manuscript and performed the data visualization. XC, LJ and TZ supervised the study. All authors provided critical revisions of the draft and approved the submitted draft. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. XC is the guarantor.

Declaration of competing interest

None to declare.

References (70)

  • R.D. Santos et al.

    Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps

    Atherosclerosis

    (2019)
  • N. Stefan et al.

    Phenotypes of prediabetes and stratification of cardiometabolic risk

    Lancet Diabetes Endocrinol

    (2016)
  • A. Deprince et al.

    Dysregulated lipid metabolism links NAFLD to cardiovascular disease

    Mol Metab

    (2020)
  • A. Mantovani et al.

    Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

    Lancet Gastroenterol Hepatol

    (2021)
  • H. Peng et al.

    Nonalcoholic fatty liver disease and cardiovascular diseases: a Mendelian randomization study

    Metabolism

    (2022)
  • A. Mantovani et al.

    Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week

    J Am Coll Cardiol

    (2022)
  • N. Simons et al.

    PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease

    Gastroenterology

    (2017)
  • E. Ferrannini et al.

    Diabetes and hypertension: the bad companions

    Lancet

    (2012)
  • U.L. Sreedhar et al.

    A systematic review of intra-pancreatic fat deposition and pancreatic carcinogenesis

    J Gastrointest Surg

    (2020)
  • T.B. Zhu et al.

    Lipid metabolism in Alzheimer's disease

    Brain Res Bull

    (2019)
  • A. Serrano-Pozo et al.

    APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches

    Lancet Neurol

    (2021)
  • O. Jamialahmadi et al.

    Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease

    Gastroenterology

    (2021)
  • L. Valenzuela-Vallejo et al.

    Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)

    Metabolism

    (2022)
  • F. Bril

    What the new definition of metabolic dysfunction-associated fatty liver disease (MAFLD) left behind: genetically acquired fatty liver disease (GAFLD)

    EBioMedicine

    (2021)
  • M.H. Le et al.

    2019 global NAFLD prevalence: a systematic review and meta-analysis

    Clin Gastroenterol Hepatol

    (2021)
  • L. Alon et al.

    Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis

    EurJ Prev Cardiol

    (2022)
  • J. Xu et al.

    Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events

    Stroke

    (2021)
  • D.H. Sinn et al.

    Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study

    J Gastroenterol Hepatol

    (2020)
  • M. Alexander et al.

    Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults

    BMJ

    (2019)
  • G. Davey Smith et al.

    Mendelian randomization: genetic anchors for causal inference in epidemiological studies

    Hum Mol Genet

    (2014)
  • M. Wu et al.

    Non-alcoholic fatty liver disease and stroke: a Mendelian randomization study

    Eur J Neurol

    (2022)
  • B.K. Lauridsen et al.

    Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals

    Eur Heart J

    (2018)
  • M. Brouwers et al.

    Relationship between nonalcoholic fatty liver disease susceptibility genes and coronary artery disease

    Hepatol Commun

    (2019)
  • M. Vujkovic et al.

    A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

    Nat Genet

    (2022)
  • S. Burgess et al.

    Interpreting findings from Mendelian randomization using the MR-egger method

    Eur J Epidemiol

    (2017)
  • Cited by (14)

    View all citing articles on Scopus
    View full text